Skip to main content
SpringerLink
Log in

Bromocriptine in the Treatment of Parkinsonism

  • Evaluations on New Drug
  • Published:
Drugs Aims and scope Submit manuscript

Summary

Bromocriptine alters the motor behaviour of animals and improves the motor defect of parkinsonism. Changes in movement are accompanied by biochemical changes in the central nervous system, consistent with the idea that bromocriptine has a dopamine agonist action in the basal ganglia and also in the mesolimbic system and hypothalamus. The overall antiparkinsonian effect of bromocriptine is similar to that of 1- dopa alone or with benserazide (a decarboxylase inhibitor) when optimum doses are used, although individual patients may respond better to 1 drug than to the other.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Anden, N-E.; Carlsson, A.; Kerstell, J.; Magnusson, T.; Olsson, R.; Roos, B-E.; Steen, B.; Steg, G.; Svanborg, A.; Thieme, G. and Werdinius, B.: Oral L-dopa treatment of Parkinsonism. Acta Medica Scandinavica 187: 247 (1970)

    Article  PubMed  CAS  Google Scholar 

  • Bedard, P.; Parkes, J.D. and Marsden, C.D.: Effect of new dopamine-blocking agent (oxiperomide) on drug-induced dyskinesias in Parkinson’s disease and spontaneous dyskinesias. British Medical Journal 1: 954 (1978)

    Article  PubMed  CAS  Google Scholar 

  • Besser, G.M.; Thorner, M.O.; Wass, J.A.M.; Doniach, I.; Canti, G.; Curling, M.; Grudzinskas, J.G. and Setchell, M.E.: Absence of uterine neoplasms in patients on bromocriptine. British Medical Journal 2: 868 (1977)

    Article  PubMed  CAS  Google Scholar 

  • Birkmayer, W.: Medical Treatment of Parkinson’s Disease: General Review, Past and Present; in Birkmayer and Hornykiewicz (Eds) Advances in Parkinsonism, p.407 (pmEditiones Roche, Basle 1976)

    Google Scholar 

  • Calne, D.B.; Brennan, J.; Spiers, A.S.D. and Stern, G.M.: Hypotension caused by L-dopa. British Medical Journal 1: 474 (1970)

    Article  PubMed  CAS  Google Scholar 

  • Calne, D.B., Teychenne, P.F.; Claveria, L.E.: Eastman, R.; Greenacre, J.K. and Petrie, A.: Bromocriptine in Parkinsonism. British Medical Journal 4: 442 (1974) a

    Article  PubMed  CAS  Google Scholar 

  • Calne, D.B.; Teychenne, P.F.; Leigh, P.N.; Bamji, A.N. and Greenacre, J.K.: Treatment of Parkinsonism with bromocriptine. Lancet 2: 1355 (1974)b

    Article  PubMed  CAS  Google Scholar 

  • Calne, D.B.; Williams, A.C.; Neophytides, A.; Plotkin, C.; Nutt, J.G. and Teychenne, P.F.: Long-term treatment of Parkinsonism with Bromocriptine. Lancet 1: 735 (1978)

    Article  PubMed  CAS  Google Scholar 

  • Caraceni, T.A.; Celano, I.; Parati, E. and Girotti, F.: Bromocriptine alone or associated with L-dopa plus benserazide in Parkinson’s Disease. Journal of Neurology, Neurosurgery and Psychiatry 40: 1142 (1977)

    Article  CAS  Google Scholar 

  • Clark, B.J.; Scholtysik, G. and Fluckiger, E.: Cardiovascular actions of Bromocriptine. Acta Endocrinologica 88(Suppl. 216): 75 (1978)

    CAS  Google Scholar 

  • Corrodi, H.; Fuxe, K.; Hokfelt, T.; Lidbrink, P. and Ungerstedt, U.: Effect of ergot drugs on central catecholamine neurones: evidence for stimulation of central dopamine neurones. Journal of Pharmacy and Pharmacology 25: 409 (1973)

    Article  PubMed  CAS  Google Scholar 

  • Corrodi, H.; Fuxe, K. and Ungerstedt, U.: Evidence for a new type of dopamine receptor stimulating agent. Journal of Pharmacy and Pharmacology 23: 989 (1971)

    Article  PubMed  CAS  Google Scholar 

  • Costall, B. and Naylor, R.J.: Neuroleptic antagonism of dyskinetic phenomena. European Journal of Pharmacology 33: 301 (1975)

    Article  PubMed  CAS  Google Scholar 

  • Costall, B. and Naylor, R.J.: Apomorphine as an antagonist of the dopamine response from the nucleus accumbens. Journal of Pharmacy and Pharmacology 28: 592 (1976)

    Article  PubMed  CAS  Google Scholar 

  • Cotzias, G.C.; Papavasiliou, P.S.; Tolosa, E.S.; Mendez, J.S. and Bell-Midura, M.: Treatment of Parkinson’s disease with apomorphines. Possible role of growth hormone. New England Journal of Medicine 294: 567 (1976)

    Article  PubMed  CAS  Google Scholar 

  • Dolphin, A.C.; Jenner, P.; Sawaya, M.C.B.; Marsden, C.D. and Testa, B.: The effect of bromocriptine on locomotor activity and cerebral catecholamines in rodents. Journal of Pharmacy and Pharmacology 29: 727 (1977)

    Article  PubMed  CAS  Google Scholar 

  • Duvoisin, R.: Digital vasospasm with bromocriptine. Lancet 2: 204 (1976)

    Article  PubMed  CAS  Google Scholar 

  • Editorial. Drugs for Parkinson’s Disease. Lancet 1: 754 (1978)

  • Fuxe, K.; Agnati, L.F.; Corrodi, H.; Everett, B.J.; Hokfelt, T.; Loestrom, A. and Ungerstedt, U.: Action of dopamine receptor agonists in forebrain and hypothalamus: rotational behaviour, ovulation and dopamine turnover; in Calne, Chase and Barbeau (Eds) Advances in Neurology, vol. 9. p.223 (Raven Press, New York 1975)

    Google Scholar 

  • Fuxe, K.; Corrodi, H.; Hokfelt, T.; Lidbrink, P. and Ungerstedt, U.: Ergocornine and 2-Br-α-ergocryptine. Evidence for prolonged dopamine receptor stimulation. Medical Biology 52: 121 (1974)

    PubMed  CAS  Google Scholar 

  • Fuxe, K.; Fredholm, B.B.; Ogren, S.O.; Agnati, L.F.; Hokfelt, T. and Gustafsson, J.A.: Pharmacological and biochemical evidence for the dopamine agonist effect of bromocriptine. Acta Endocrinologica 88(Suppl. 216): 27 (1978)

    CAS  Google Scholar 

  • Galea-Debono, A.G.; Jenner, P.; Marsden, C.D.; Parkes, J.D.; Tassy, D. and Walters, J.: Plasma dopa levels and growth hormone response to levodopa in parkinsonism. Journal of Neurology, Neurosurgery and Psychiatry 40: 162 (1977)

    Article  CAS  Google Scholar 

  • Gerlach, J.: Effect of CB-154 (2-bromo-alpha-ergocryptine) on paralysis agitans compared with Madopar in a double-blind, cross-over trial. Acta Neurologica Scandinavica 53:189 (1976)

    Article  PubMed  CAS  Google Scholar 

  • Ginos, J.Z.; Cotzias, G.C. and Tolosa, E.: Cholinergic effects of molecular segments of apomorphine and dopaminergic effects of N, N-dealkylated dopamine. Journal of Medicinal Chemistry 18: 1194 (1975)

    Article  PubMed  CAS  Google Scholar 

  • Godwin-Austen, R.B. and Smith, N.J.: Comparison of effects of bromocriptine and levodopa in Parkinson’s disease. Journal of Neurology, Neurosurgery and Psychiatry 40: 479 (1977)

    Article  CAS  Google Scholar 

  • Goldstein, M.; Bronaugh, R.L.; Low, J.Y.; Ohashi, T.; Drummond, G.S. and Fuxe, K.: Nonstriatal Dopaminergic Neurones; in Costa and Gessa (Eds) Advances in Biochemical Psychopharmacology, vol. 16, p.447 (Raven Press, New York 1977)

    Google Scholar 

  • Goldstein, M.; Low, J.Y. and Hata, F.: Binding interactions of ergot alkaloids with monoaminergic receptors in the brain. European Journal of Pharmacology. In press (1979)

  • Greenacre, J.K.; Teychenne, P.F.; Petrie, A.; Calne, D.B.; Leigh, P.N. and Reid, J.: The cardiovascular effects of bromocriptine in parkinsonism. British Journal of Clinical Pharmacology 3: 571 (1976)

    Article  PubMed  CAS  Google Scholar 

  • Greengard, P.; McAfee, D.A. and Kebabian, J.W.: On the mechanism of action of cyclic AMP and its role in synaptic transmission; in Greengard and Robison (Eds) Advances in Cyclic Neucleotide Research, vol. 1, p.337 (Raven Press, New York 1972)

    Google Scholar 

  • Griffith, R.W.: Bromocriptine and uterine neoplasms. British Medical Journal 2: 1605 (1977)

    Article  PubMed  CAS  Google Scholar 

  • Gron, U.: Bromocriptine versus placebo in levodopa treated patients with Parkinson’s Disease. Acta Neurologica Scandinavica 56: 269 (1977)

    Article  PubMed  CAS  Google Scholar 

  • Johnson, A.M.; Loew, D.M. and Vigouret, J.M.: Stimulant properties of bromocriptine on central dopamine receptors in comparison to apomorphine, (+)— amphetamine and L-DOPA. British Journal of Pharmacology 56: 59 (1976)

    Article  PubMed  CAS  Google Scholar 

  • Johnson, A.M.; Vigouret, J.M. and Loew, D.M.: Central dopaminergic actions of ergotoxine alkaloids and some derivatives. Experientia 29: 763 (1973)

    Google Scholar 

  • Kartzinel, R. and Calne, D.B.: Studies with bromocriptine. Part I. ‘On-off’ phenomena. Neurology (Minneapolis) 26: 508 (1976)

    Article  Google Scholar 

  • Kartzinel, R.; Shoulson, I. and Calne, D.B.: Studies with bromocriptine. Part 2. Double-blind comparison with L-dopa in idiopathic parkinsonism. Neurology (Minneapolis) 26: 517 (1976) a

    Article  Google Scholar 

  • Kartzinel, R.; Shoulson, I. and Calne, D.B.: Studies with bromocriptine III. Concomitant administration of caffeine to patients with idiopathic parkinsonism. Neurology (Minneapolis) 26: 741 (1976)b

    Article  CAS  Google Scholar 

  • Kartzinel, R.; Teychenne, P.; Gillespie, M.M.; Perlow, M., Gielen, A.C.; Sadowsky, D.A. and Calne, D.B.: Bromocriptine and levodopa (with or without carbidopa) in parkinsonism. Lancet 2: 272 (1976)c

    Article  PubMed  CAS  Google Scholar 

  • Kristensen, O. and Hansen, E.: Bromocriptine in the treatment of advanced parkinsonism. Acta Neurologica Scandinavica 56: 274 (1977)

    Article  PubMed  CAS  Google Scholar 

  • Lieberman, A.N.: Treatment of Parkinson’s Disease with Bromocriptine. New England Journal of Medicine 297: 508 (1977)

    Google Scholar 

  • Lieberman, A.M.; Kupersmith, M.; Estey, E. and Goldstein, M.: Lergotrile in Parkinson’s disease. Lancet 2: 515 (1976)a

    Article  Google Scholar 

  • Lieberman, A.; Kupersmith, M.; Estey, E. and Goldstein, M.: Treatment of Parkinson’s disease with bromocriptine. New England Journal of Medicine 295:1400 (1976) b

    Article  PubMed  CAS  Google Scholar 

  • Lieberman, A.; Miyamoto, T.; Battista, A.F. and Goldstein, M.: Studies on the antiparkinsonian efficacy of lergotrile. Neurology (Minneapolis) 25: 459 (1975)

    Article  CAS  Google Scholar 

  • Lieberman, A.; Zolfaghari, M.; Boal, D.; Hassouri, H.; Vogel, B.; Battista, A.; Fuxe, K. and Goldstein, M.: The antiparkinsonian efficacy of bromocriptine. Neurology (Minneapolis) 26: 405 (1976) c

    Article  CAS  Google Scholar 

  • Loew, D.M.; Van Duesen, E.B. and Meier-Ruge, W.: Effects on the Central Nervous System; in Berde and Schild (Eds) Ergot Alkaloids and Related Compounds vol. 49 p.420 Heffter-Heubner Handbook of Experimental Pharmacology (Springer-Verlag, Berlin 1978)

    Google Scholar 

  • Marsden, C.D. and Parkes, J.D.: ’On-off’ effects in patients with Parkinson’s disease on chronic levodopa therapy. Lancet 1: 292 (1976)

    Article  PubMed  CAS  Google Scholar 

  • Olson, L.; Nystrom, B. and Seiger, A.: Monoamine fluorescence histochemistry of human post-mortem brain. Brain Research 63: 231 (1973)

    Article  PubMed  CAS  Google Scholar 

  • Parkes, J.D.; Debono, A.G. and Marsden, C.D.: Bromocriptine in Parkinsonism: Long-term treatment, dose-response, and comparison with levodopa. Journal of Neurology, Neurosurgery and Psychiatry 39: 1101 (1976)

    Article  CAS  Google Scholar 

  • Parkes, J.D.; Price, P.A. and Massden, C.D.: Movement, growth hormone and prolactin responses to dopamine and dopamine agonists; in Legg (Ed) Neurotransmitter Systems and their Clinical Disorders, p.115 (Academic Press, London 1978)

    Google Scholar 

  • Pinder, R.M.; Brogden, R.N.; Sawyer, P.R.; Speight, T.M. and Avery, G.S.: Metoclopramide: a review of its pharmacological properties and clinical use. Drugs 12: 81 (1976)

    Article  PubMed  CAS  Google Scholar 

  • Price, P.; Debono, A.; Parkes, J.D.; Marsden, C.D. and Rosenthaler, J.: Plasma bromocriptine levels, clinical and growth hormone responses in parkinsonism. British Journal of Clinical Pharmacology 6: 303 (1978)

    Article  PubMed  CAS  Google Scholar 

  • Puech, A.J.; Simon, P.; Chermat, R. and Boissier, J.R.: Bromocriptin and Methylergometrine: Pharmacological approach of the mechanism of their central effects. Pharmacology Research Communications 9: 299 (1977)

    Article  CAS  Google Scholar 

  • Reid, J.L.; Calne, D.B.; George, C.F. and Vakil, S.D.: Levodopa and pressor amine sensitivity in parkinsonism. Clinical Science 43: 851 (1972)

    PubMed  CAS  Google Scholar 

  • Rinne, U.K.; Marttila, R. and Sonninen. V.: Brain dopamine turnover and the relief of parkinsonism. Archives of Neurology 34: 626 (1977)

    Article  PubMed  CAS  Google Scholar 

  • Schnieden, H. and Cox, B.: A comparison between amantadine and bromocriptine using the stereotyped behaviour response (SBR) in the rat. European Journal of Pharmacology 39: 133 (1976)

    Article  PubMed  CAS  Google Scholar 

  • Smith, R.C.; Tamminga, C.A.; Haraszti, J.; Ghanshyam, N.P. and Davis, J.M.: Effects of dopamine agonists in tardive dyskinesia. American Journal of Psychiatry 134: 763 (1977)

    PubMed  CAS  Google Scholar 

  • Snider, S.R.; Hutt, C.; Stein, B.; Prasad, A.L.N. and Fahn, S.: Correlation of behavioural inhibition or excitation produced by bromocriptine with changes in brain catecholamine turnover. Journal of Pharmacy and Pharmacology 28: 563 (1976)

    Article  PubMed  CAS  Google Scholar 

  • Teychenne, P.F.; Calne, D.B.; Leigh, P.N.; Greenacre, J.K.; Reid, J.L.; Petrie, A. and Bamji, A.N.: Idiopathic parkinsonism treated with bromocriptine. Lancet 2: 473 (1975)

    Article  PubMed  CAS  Google Scholar 

  • Trabucchi, M.; Andreoli, V.M.; Frattola, L. and Spano, P.F.: Pre-and Postsynaptic Action of Bromocriptine: Its Pharmacological Effects in Schizophrenic and Neurological Diseases; in Costa and Gessa (Eds) Advances in Biochemical Pharmacology, vol. 16 p.661 (Raven Press, New York 1977)

    Google Scholar 

  • Trabucchi, M.; Spano, P.F.; Tonon, G.C. and Frattola, L.: Effects of bromocriptine on cerebral dopaminergic receptors. Life Sciences 19: 225 (1976)

    Article  PubMed  CAS  Google Scholar 

  • Ungerstedt, U.: The role of dopamine as a neurotransmitter in the central and autonomic nervous system. Acta Endocrinologia 88 (Suppl. 216): 13 (1978)

    CAS  Google Scholar 

  • Wass, J.A.H.; Thorner, M.O. and Besser, G.M.: Digital vasospasm with bromocriptine. Lancet 1: 1135 (1976)

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, King’s College Hospital and Institute of Psychiatry, Denmark Hill, London, SE 59RS, England

    J. D. Parkes

Authors
  1. J. D. Parkes
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Parkes, J.D. Bromocriptine in the Treatment of Parkinsonism. Drugs 17, 365–382 (1979). https://doi.org/10.2165/00003495-197917050-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-197917050-00006

Keywords

Search

Navigation